Unity Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Unity Biotechnology has a total shareholder equity of $28.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $65.7M and $37.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$43.20m |
Equity | US$28.40m |
Total liabilities | US$37.29m |
Total assets | US$65.69m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9U9's short term assets ($46.6M) exceed its short term liabilities ($7.8M).
Long Term Liabilities: 9U9's short term assets ($46.6M) exceed its long term liabilities ($29.5M).
Debt to Equity History and Analysis
Debt Level: 9U9 is debt free.
Reducing Debt: 9U9 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9U9 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9U9 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 4.9% each year.